Literature DB >> 10504016

Increased adenoid mast cells in patients with otitis media with effusion.

S O Ulualp1, D Sahin, N Yilmaz, V Anadol, O Peker, O Gursan.   

Abstract

OBJECTIVE: Previous studies have been suggested the possible role of adenoid mast cells in the pathogenesis of otitis media with effusion (OME). The aim of the present study was to evaluate the possible relationship of adenoid mast cells and hearing loss in patients with chronic OME.
METHODS: Twenty patients with combined chronic OME and chronic adenoiditis (OME-A) and 20 patients with isolated chronic adenoiditis were studied. Hearing thresholds were determined by pure tone audiometry in both groups. All subjects underwent adenoidectomy and adenoid mast cells were counted in each specimen. Number of adenoid mast cells were determined in both groups. Possible relationship of adenoid mast cells and hearing thresholds in OME-A patients was evaluated by comparing the hearing thresholds of OME-A patients with mast cell count above the mean of OME-A group and hearing thresholds of OME-A patients with mast cell count below the mean of OME-A group.
RESULTS: All isolated chronic adenoiditis patients had normal hearing thresholds. OME-A patients had hearing thresholds ranging from 12-52 dB. The number of adenoid mast cells in OME-A group (median: 80) was significantly greater than isolated chronic adenoiditis group (median: 38) (P < 0.05). OME-A patients with adenoid mast cell count above the mean of OME-A group had significantly higher hearing thresholds compared to OME-A patients with mast cell count below the mean of OME-A group (P < 0.05).
CONCLUSIONS: Patients with OME-A have greater number of adenoid mast cells than patients with isolated chronic adenoiditis. OME-A patients with adenoid mast cell count above the mean of the OME-A group had higher hearing thresholds than OME-A patients with adenoid mast cell count below the mean of the OME-A group. Increased number of adenoid mast cells may contribute to the pathogenesis of higher hearing thresholds in some OME-A patients.

Entities:  

Mesh:

Year:  1999        PMID: 10504016     DOI: 10.1016/s0165-5876(99)00043-9

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  7 in total

Review 1.  The Proposed Usage of Intranasal Steroids and Antihistamines for Otitis Media with Effusion.

Authors:  Rachel E Roditi; David S Caradonna; Jennifer J Shin
Journal:  Curr Allergy Asthma Rep       Date:  2019-09-05       Impact factor: 4.806

Review 2.  Does the type of rhinitis influence development of otitis media with effusion in children?

Authors:  Nicola Quaranta; Lucia Iannuzzi; Matteo Gelardi
Journal:  Curr Allergy Asthma Rep       Date:  2014-11       Impact factor: 4.806

Review 3.  Role of innate immunity in the pathogenesis of otitis media.

Authors:  Rahul Mittal; Joyson Kodiyan; Robert Gerring; Kalai Mathee; Jian-Dong Li; M'hamed Grati; Xue Zhong Liu
Journal:  Int J Infect Dis       Date:  2014-11-05       Impact factor: 3.623

Review 4.  Audiological investigation of otitis media in children with atopy.

Authors:  Francesco Martines; Daniela Bentivegna
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

5.  Role of adenoids and adenoiditis in children with allergy and otitis media.

Authors:  Gian Luigi Marseglia; Dimitri Poddighe; Davide Caimmi; Alessia Marseglia; Silvia Caimmi; Giorgio Ciprandi; Catherine Klersy; Fabio Pagella; Anna Maria Castellazzi
Journal:  Curr Allergy Asthma Rep       Date:  2009-11       Impact factor: 4.806

Review 6.  The Influence of Age on the Relationship Between Allergic Rhinitis and Otitis Media.

Authors:  Rachel E Roditi; Jennifer J Shin
Journal:  Curr Allergy Asthma Rep       Date:  2018-10-20       Impact factor: 4.806

7.  The Formation of Biofilm and Bacteriology in Otitis Media with Effusion in Children: A Prospective Cross-Sectional Study.

Authors:  Artur Niedzielski; Lechosław Paweł Chmielik; Tomasz Stankiewicz
Journal:  Int J Environ Res Public Health       Date:  2021-03-30       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.